The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
HIV Testing and Treatment with the Use of a Community Health Approach in Rural Africa
Open accessAbstract
BACKGROUND: Universal antiretroviral therapy (ART) with annual population testing and a multidisease, patient-centered strategy could reduce new human immunodeficiency virus (HIV) infections and improve community health. METHODS: We randomly assigned 32 rural communities in Uganda and Kenya to baseline HIV and multidisease testing and national guideline-restricted ART (control group) or to baseline testing plus annual testing, eligibility for universal ART, and patient-centered care (intervention group). The primary end point was the cumulative incidence of HIV infection at 3 years. Secondary end points included viral suppression, death, tuberculosis, hypertension control, and the change in the annual incidence of HIV infection (which was evaluated in the intervention group only). RESULTS: A total of 150,395 persons were included in the analyses. Population-level viral suppression among 15,399 HIV-infected persons was 42% at baseline and was higher in the intervention group than in the control group at 3 years (79% vs. 68%; relative prevalence, 1.15; 95% confidence interval [CI], 1.11 to 1.20). The annual incidence of HIV infection in the intervention group decreased by 32% over 3 years (from 0.43 to 0.31 cases per 100 person-years; relative rate, 0.68; 95% CI, 0.56 to 0.84). However, the 3-year cumulative incidence (704 incident HIV infections) did not differ significantly between the intervention group and the control group (0.77% and 0.81%, respectively; relative risk, 0.95; 95% CI, 0.77 to 1.17). Among HIV-infected persons, the risk of death by year 3 was 3% in the intervention group and 4% in the control group (0.99 vs. 1.29 deaths per 100 person-years; relative risk, 0.77; 95% CI, 0.64 to 0.93). The risk of HIV-associated tuberculosis or death by year 3 among HIV-infected persons was 4% in the intervention group and 5% in the control group (1.19 vs. 1.50 events per 100 person-years; relative risk, 0.79; 95% CI, 0.67 to 0.94). At 3 years, 47% of adults with hypertension in the intervention group and 37% in the control group had hypertension control (relative prevalence, 1.26; 95% CI, 1.15 to 1.39). CONCLUSIONS: Universal HIV treatment did not result in a significantly lower incidence of HIV infection than standard care, probably owing to the availability of comprehensive baseline HIV testing and the rapid expansion of ART eligibility in the control group. (Funded by the National Institutes of Health and others; SEARCH ClinicalTrials.gov number, NCT01864603.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of HIV-1 infection with early antiretroviral therapy.
Cohen, M. S., Chen, Y. Q., McCauley, M., Gamble, T., Hosseinipour, M. C., Kumarasamy, N., Hakim, J. G., Kumwenda, J., Grinsztejn, B., Pilotto, J. H. S., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105243 · Cited by 6,873
Self-citationUnderstanding Sustained Retention in HIV/AIDS Care and Treatment: a Synthetic Review
Roy, M., Czaicki, N., Holmes, C., Chavan, S., Tsitsi, A., Odeny, T., Sikazwe, I., Padian, N., & Geng, E. (2016) · Current HIV/AIDS Reports · doi:10.1007/s11904-016-0317-9 · Cited by 35
Cited by
Achieving the 95 95 95 targets for all: A pathway to ending AIDS
Frescura, L., Godfrey-Faussett, P., Feizzadeh, A., El-Sadr, W., Syarif, O., Ghys, P. D., & on behalf of the 2025 testing treatment target Working Group (2022) · PLOS ONE · doi:10.1371/journal.pone.0272405 · Cited by 442
Effect of Universal Testing and Treatment on HIV Incidence — HPTN 071 (PopART)
Hayes, R. J., Donnell, D., Floyd, S., Mandla, N., Bwalya, J., Sabapathy, K., Yang, B., Phiri, M., Schaap, A., Eshleman, S. H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814556 · Cited by 337
Khan, S., Spiegelman, D., Walsh, F., Mazibuko, S., Pasipamire, M., Chai, B., Reis, R., Mlambo, K., Delva, W., Khumalo, G., et al. (2020) · Journal of the International AIDS Society · doi:10.1002/jia2.25610 · Cited by 32
Metadata
- Authors
- Havlir, D. V., Balzer, L. B., Charlebois, E. D., Clark, T. D., Kwarisiima, D., Ayieko, J., Kabami, J., Sang, N., Liegler, T., Chamie, G., Camlin, C. S., Jain, V., Kadede, K., Atukunda, M., Ruel, T., Shade, S. B., Ssemmondo, E., Byonanebye, D. M., Mwangwa, F., Owaraganise, A., Olilo, W., Black, D., Snyman, K., Burger, R., Getahun, M., Achando, J., Awuonda, B., Nakato, H., Kironde, J., Okiror, S., Thirumurthy, H., Koss, C., Brown, L., Marquez, C., Schwab, J., Lavoy, G., Plenty, A., Mugoma Wafula, E., Omanya, P., Chen, Y.-H., Rooney, J. F., Bacon, M., van der Laan, M., Cohen, C. R., Bukusi, E., Kamya, M. R., & Petersen, M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-07-18
- Volume
- 381
- Issue
- 3
- Pages
- 219-229
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2960675107
- Cited by
- 212
- References
- 2
- FWCI
- 23.68
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.